MRVI241220C2500
- 2.20
- 0.000.00%
Maravai LifeSciences Newsroom
Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating
Craig-Hallum Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)
Goldman Sachs Downgrades Maravai LifeSciences(MRVI.US) to Sell Rating
Goldman Sachs Downgrades Maravai Lifesciences to Sell From Neutral, Cuts Price Target to $4.25 From $7
Maravai LifeSciences Initiated at Peer Perform by Wolfe Research
Maravai LifeSciences Analyst Ratings
Wolfe Research Initiates Maravai LifeSciences(MRVI.US) With Hold Rating
Morgan Stanley Maintains Maravai LifeSciences(MRVI.US) With Hold Rating, Cuts Target Price to $7
Hold Rating on Maravai Lifesciences: Revenue Miss, Guidance Cut, and Market Challenges Amid Potential Upside From Officinae Bio Acquisition
UBS Adjusts Price Target on Maravai Lifesciences to $8 From $11, Maintains Neutral Rating
Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $12
BofA Securities Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $9
Maravai LifeSciences Cut to Market Perform From Outperform by William Blair
Baird Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $9
RBC Capital Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $13
Maravai LifeSciences Analyst Ratings
Baird Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $9
RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)
William Blair Downgrades Maravai LifeSciences(MRVI.US) to Hold Rating
RBC Capital Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Raises Target Price to $17